Increased testing for heart disease indicator needed worldwide, say experts

Credit: Pixabay/CC0 Public Domain A review in The Lancet finds that 20% of the world population carries a genetic risk factor for cardiovascular diseases such as heart attacks, strokes, and

SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack

Credit: Pixabay/CC0 Public Domain The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI),

Beta-blockers do not affect patients’ quality of life, study finds

Credit: CC0 Public Domain Long-term use of beta-blockers in patients with myocardial infarction and preserved heart function does not significantly change quality of life or well-being compared to no beta-blockers.